Biosimilars – Blood on the patent dance floor
With the Federal Circuit last week issuing an important decision involving biosimilars in Sandoz v Amgen, Marion Webb reports on the issues at play in the coming patent war between biosimilar and innovative companies
Ever since the Biologics Price Competition and Innovation Act (BPCIA) was enacted in 2009 as part of the Patient Protection and Affordable Care Act, uncertainty has dogged the biologics industry about how it would operate in practice....
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.